Free Trial
NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

Bicycle Therapeutics logo
$7.06 -0.02 (-0.34%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Key Stats

Today's Range
$7.12
$7.14
50-Day Range
$6.95
$8.71
52-Week Range
$6.10
$28.67
Volume
649 shs
Average Volume
315,979 shs
Market Capitalization
$488.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.22
Consensus Rating
Moderate Buy

Company Overview

Bicycle Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

BCYC MarketRank™: 

Bicycle Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 304th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bicycle Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bicycle Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bicycle Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bicycle Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bicycle Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bicycle Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.11% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently decreased by 23.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bicycle Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicycle Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.11% of the float of Bicycle Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicycle Therapeutics has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Bicycle Therapeutics has recently decreased by 23.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bicycle Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Bicycle Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for BCYC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $58,820.00 in company stock.

  • Percentage Held by Insiders

    22.90% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bicycle Therapeutics' insider trading history.
Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCYC Stock News Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Bicycle (BCYC) Q2 Revenue Falls 69%
See More Headlines

BCYC Stock Analysis - Frequently Asked Questions

Bicycle Therapeutics' stock was trading at $14.00 at the beginning of the year. Since then, BCYC shares have decreased by 49.4% and is now trading at $7.08.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) released its earnings results on Friday, August, 8th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.19. The company earned $2.90 million during the quarter, compared to analyst estimates of $9.43 million. Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative trailing twelve-month return on equity of 32.43%.

Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional shareholders of Bicycle Therapeutics include Armistice Capital LLC (4.04%), Westfield Capital Management Co. LP (4.02%), Candriam S.C.A. (1.69%) and Tybourne Capital Management HK Ltd. (1.44%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Michael Skynner, Alistair Milnes, Santiago Arroyo, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett, Alethia Young, Travis Alvin Thompson and Lee Kalowski.
View institutional ownership trends
.

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Grayscale Ethereum Trust (ETH) (ETHE), Curaleaf (CURLF) and Marathon Oil (MRO).

Company Calendar

Last Earnings
8/08/2025
Today
8/29/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCYC
CIK
1761612
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

High Price Target
$44.00
Low Price Target
$10.00
Potential Upside/Downside
+213.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$169.03 million
Net Margins
-1,257.00%
Pretax Margin
-1,287.33%
Return on Equity
-32.43%
Return on Assets
-26.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.39
Quick Ratio
10.39

Sales & Book Value

Annual Sales
$35.28 million
Price / Sales
13.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.66 per share
Price / Book
0.73

Miscellaneous

Outstanding Shares
69,250,000
Free Float
53,395,000
Market Cap
$490.29 million
Optionable
Optionable
Beta
1.44

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:BCYC) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners